the PKGIα LZ domain leads to accelerated HF and cardiac remodeling in response to LV pressure overload by transaortic constriction (TAC), 3 supporting an important role of PKGIα LZ substrates in attenuating pathological remodeling. However, these PKGIα LZ-binding substrates specific to the myocardium have not been explored.
We therefore undertook the present study to identify PKGIα LZ-binding partners as candidate antiremodeling substrates in the myocardium. To this end, we designed a molecular screen for myocardial PKGIα LZ-binding molecules. Here, we describe the identification of cardiac myosin-binding protein-C (cMyBP-C), a CM-specific protein and critical inhibitor of cardiac remodeling, as a PKGIα LZ-binding partner and kinase substrate.
Methods

Preparation of GST Fusion Proteins
pGEX plasmids containing the N-terminal amino acids 1 to 59 of the wild-type (WT) PKGIα LZ domain (PKGIα 1 to 59 ), mutated LZ domain (PKGIα LZM ), and glutathione S-transferase (GST) alone were transformed into BL21, as described. 12 Bacteria were treated with isopropyl beta-D-1-thioglactopyranoside (0.2 mmol/L×2.5 hours at 25°) to induce protein translation, followed by generation of GSTfusion beads as described. 12 
Myocardial Screen
Hearts of C57/Bl6 male mice were rapidly excised and snap frozen in liquid nitrogen, followed by dounce homogenization of the left ventricle (LV) in lysis buffer as described previously. 3 LV lysates were rocked gently overnight at 4° with fusion protein beads, followed by washing 3 times with lysis buffer. Proteins were eluted off the beads by boiling for 5 minutes in Laemmli sample buffer, followed by separation by SDS-PAGE and Coomassie staining. Bands, which were visible in the PKGIα 1-59 but not GST or PKGIα LZM lanes, were excised from the gel. Figure 1A outlines the general screening strategy.
Protein bands were analyzed by mass spectroscopy at the Harvard Taplin Mass Spectroscopy facility as described. 13 
Western Blotting
GST pulldowns and PKGI precipitation with cGMP and RP-8AET-cGMPS fusion beads were performed as described. 14 Western blotting for PKGIα and cMyBP-C was performed with anti-PKGIα 14 and anti-cMyBP-C (Santa Cruz) antibodies at 1:1000 and 1:100, respectively. For in vivo phosphorylation studies, antibodies to cMyBP-C phosphoserines Ser-273, Ser-282, or Ser-302 (1:2000 dilution) were used as described. 15 
Cotransfection Experiments
CV-1 in Origin, carrying the SV40 genetic material (COS) cells were transfected with full-length cMyBP-C, a plasmid containing the human cytomegalovirus major intermediate-early gene enhancer region (termed the pCI vector), and with either WT or LZM PKGIα in pCI. Cells were treated with 100 μmol/L 8Br-cGMP for 10 minutes and with 20 mmol/L KT 5720, a selective cAMP-dependent protein kinase A inhibitor, to prevent potential nonspecific cGMP-induced protein kinase A activation. Cells were lysed as described, 14 and samples subjected to SDS-PAGE and Western blot.
In Vitro Phosphorylation of cMyBP-C by PKGlα
Recombinant mouse His-tagged cMyBP-C spanning the C0-C1-M-C2 domains was generated in Escherichia Coli using a plasmid expression vector driven by the T7 promoter (pET expression system). Recombinant PKGlα (4 U; Cat no. CY-E1161-2, MBL International Corporation, Woburn, MA) was incubated with 100 ng of His-tagged cMyBP-C for 30 minutes at 37°C. Reactions were incubated with either vehicle or with 100 μmol/L 8Br-cGMP. Reactions were stopped with 2× loading dye and heat denaturation. Proteins were resolved on 4% to 15% SDS-PAGE gels, followed by Western blot analyses against anti-C0 domain-specific antibodies for cMyBP-C, and antiphospho-specific antibodies against Ser-273, Ser-282, and Ser-302. 15 The C0-C1-M-C2 domain was also detected by silver stain. In the phosphorylation assay, a specific PKGlα inhibitor Rp-8-pCPT-cGMP (MBL International Corporation, Woburn, MA) was used as described in the manufacturer protocol.
Cardiac Myocyte Culture
Adult rat ventricular myocytes were isolated as previously described 16 with the following modifications. Adult rat ventricular myocytes were obtained from adult male Sprague-Dawley rats (Harlan Laboratories, 175-200 g) and were plated at a nonconfluent density (25-50 cells/mm 2 ) on laminin-coated dishes in DMEM low-glucose media (Invitrogen, 12320-032) supplemented with 0.1% penicillin-streptomycin. After 1 hour of plating, the media were replaced, and the cells were used for experimentation the following day as indicated in the figure legends.
Animal Models
All studies were performed under institutional approval by the Tufts Institutional Animal Care and Use Committee. TAC was performed as described 2,17 for a duration of 5 weeks. Sildenafil was administered orally at a dose of 200 mg/kg per day as described, 17 beginning 1 week after TAC.
Statistical Analysis
Quantitative data are presented as dot plots with the sample mean denoted by a horizontal bar. Two-sample comparisons were analyzed by the Mann-Whitney rank sum test. Multiple groups were compared A, Outline of screening strategy. GST fusion proteins were generated containing the PKGIα LZ domain (PKG 1-59 ), the PKGIα-mutated LZ domain (PKG LZM ), or GST alone. The separate bait proteins were incubated with left ventricular protein lysates, followed by SDS-PAGE and Coomassie staining. Protein bands selectively precipitating with PKG 1-59 were removed and identified by mass spectroscopy. B, Representative Coomassie stain from left ventricular protein lysates incubated with GST fusion proteins. The 150-kDa band visible only in PKG 1-59 precipitate (denoted by arrow) was excised and subjected to mass spectroscopy, revealing cardiac myosin-binding protein-C (cMyBP-C) as the predominant species. The thick bands between 25 and 30 kDa represent GST fusion proteins. Representative of 3 independent experiments. LV indicates left ventricle.
using Kruskal-Wallis 1-way ANOVA on ranks, followed by multiple comparison testing with the Tukey method (or Dunn method if group sizes differed). Multiple comparisons were performed if the initial Kruskal-Wallis test was significant or near significant, as described in the figure legends. Data were analyzed with SigmaPlot version 12.5.
Results
Identification of Cardiac Myosin Protein-C Through a Screen for PKGIα LZ Interacting Proteins
To screen for specific PKGIα LZ interacting proteins in the myocardium, we incubated LV lysates with GST fused to: the WT PKGIα LZ domain (PKG 1-59 ); the PKGIα LZ mutant domain (PKG LZM ); or with GST alone, followed by separation by SDS-PAGE and Coomassie staining. Figure 1A outlines the screening strategy. The Coomassie stain identified a band at ≈150 kDa, detected only in the PKG 1-59 pulldowns (Figure 1 ). Mass spectroscopy revealed cMyBP-C as the predominant protein in the band. cMyBP-C is a CM-specific protein, which is required for normal CM and LV diastolic and systolic function, 18, 19 although its regulation by PKGIα has not been described. Of note, in other PKG 1-59 -specific bands, we also detected proteins previously shown to bind the PKGIα LZ domain, including troponin I 20 and PKGIα, which is known to form a homodimer through LZ-LZ interactions. 21 We therefore explored this potential PKGIα-cMyBP-C binding further. To confirm that the PKGIα LZ domain precipitates cMyBP-C, we performed, on the same GST pulldown samples, Western blotting for cMyBP-C. cMyBP-C was detected with the PKG 1-59 , pulldown, but not PKG LZM or GST alone (Figure 2A ), supporting a specific interaction with the WT LZ domain. We next tested whether full-length PKGIα also complexes with cMyBP-C in the LV. We incubated LV lysates with agaroseconjugated cGMP and RP-8AET-cGMP beads, which each bind PKGI with high affinity and activate or inhibit PKGI kinase activity, respectively. 14 Precipitation of PKGI with either of the cGMP-linked beads, but not with control agarose beads, coprecipitated cMyBP-C ( Figure 2B ), supporting cointeraction of native PKGIα and cMyBP-C in the myocardium.
Requirement of PKGIα LZ Domain for Phosphorylation of Full-Length cMyBP-C
cMyBP-C contains multiple phosphorylation sites, including 3 serine residues on the M-domain (Ser-273, Ser-282, and Ser-302). 22 Prior studies identified that phosphorylation of cMyBP-C on these 3 M-domain sites by protein kinase A improves cardiac myocyte (CM) and LV systolic and diastolic function. [23] [24] [25] In addition, phosphorylation status of these sites inhibits pathological remodeling in vivo. 15, 26 Group-based phosphorylation scoring analysis 27 of cMyBP-C strongly predicted PKGI phosphorylation at each of these 3 sites ( Figure 3A ). We therefore tested the requirement of the PKGIα LZ domain for the phosphorylation of full-length cMyBP-C. We cotransfected COS cells with full-length cMyBP-C and either WT PKGIα or LZ mutant PKGIα. 14 The membranepermeable cGMP analogue 8Br-cGMP (100 μmol/L) induced cMyBP-C phosphorylation at Ser-273, Ser-282, and Ser-302 in WT PKGIα transfected cells (fold increase p/T cMyBP-C induced by 8Br-cGMP: 1.63±0.19, 1.66±0.02, and 1.92±0.19 arbitrary densitometric units (ADUs) in serine 273, 282, and 302, respectively). However, 8Br-cGMP failed to induce phosphorylation at these residues in the cells transfected with LZ mutant PKGIα (Figure 3 ). These findings support that cGMP induces PKGIα phosphorylation of cMyBP-C, and moreover that the PKGIα LZ domain is required for this cGMP-induced phosphorylation. Figure 4 ). Furthermore, the PKGI-specific inhibitor Rp-8pCPTcGMP decreased PKGIα-induced phosphorylation of these 3 sites (Figure 4 ), supporting the specificity of this reaction.
Direct PKGIα Phosphorylation of cMyBP-C
In Vivo Regulation of cMyBP-C by PKGIα in the Pressure Overloaded LV
The phosphodiesterase 5 inhibitor, sildenafil, activates PKG in the myocardium and inhibits pressure overload-induced remodeling and HF. 2 We tested whether PKGI activation with sildenafil increased cMyBP-C phosphorylation in mice subjected to LV pressure overload by TAC for 5 weeks. 2, 17 In these previously reported mice, sildenafil improved LV fractional shortening and reduced LV mass compared with vehicletreated mice, as well as increasing PKGI kinase activity. 17 Using cardiac tissues from these previously reported mice, 17 we measured the phosphorylation state of cMyBP-C. Compared with vehicle-treated mice, sildenafil treatment induced a 2.5±0.26-fold increase in cMyBP-C phosphorylation of 
Discussion
In this study, we performed a molecular screen for myocardial PKGIα substrates, based on the growing clinical development of PKG activation strategies to treat HF. We observed (1) selective precipitation of cMyBP-C with the PKGIα LZ-binding domain in LV lysates; (2) cointeraction of PKGIα and cMyBP-C in the heart; (3) phosphorylation of cMyBP-C by PKGIα in vitro and in cell culture in an LZ-dependent fashion, on sites previously shown to inhibit remodeling when phosphorylated; and (4) increased cMyBP-C phosphorylation on Ser-273 in response to PKGI activation with sildenafil in hearts of mice subjected to LV pressure overload. Taken together, our findings support a model in which PKGIα inhibits cardiac remodeling through phosphorylation of cMyBP-C in the myocardium, through a process mediated by LZ domain binding. We interpret these findings to reveal cMyBP-C as a novel, myocardialspecific PKGIα kinase substrate in the heart.
cMyBP-C as a Myocardial PKGIα-Interacting Protein
Our identification of cMyBP-C as a PKGIα-binding molecule supports an important role of PKGIα in regulating myocardial-specific substrates. Pharmacological activation of PKGIα attenuates LV remodeling in vivo, 2 and this requires an intact PKGIα LZ domain. 3 However, specific PKGIα substrates in the myocardium, which may mediate these effects, remain poorly understood. Previous work has identified ubiquitously expressed PKGIα substrates, such as the regulator of G protein signaling 2, as regulating the cardiac remodeling response in vivo. 28 The role, if any, of PKGIα in the myocardium has been less well appreciated, and its role in the CM in regulating remodeling remains controversial. 29, 30 More recently, CM-specific PKGI substrates have been identified, such as troponin I 20 and titin. 31 Importantly, our screen also confirmed precipitation of troponin I with the PKGIα LZ domain. PKG phosphorylation of these proteins may acutely regulate CM function, although the role of these interactions in the chronic remodeling process has not been established.
To our knowledge, our study identifies cMyBP-C as the first myocardial-specific antiremodeling molecule regulated by PKGIα. cMyBP-C functions in the sarcomere to regulate actin-myosin interaction and dynamics. Moreover, cMyBP-C is required for normal LV structure and function in vivo. Conditional deletion of cMyBP-C in mice leads to systolic and diastolic dysfunction and subsequent pathological LV remodeling. 18 Furthermore, cMyBP-C attenuates LV remodeling in response to pressure overload. 18 In humans, structural mutations in cMyBP-C represent the most common genetic cause of hypertrophic cardiomyopathy and can also lead to dilated cardiomyopathy. 32 Our observations both in vitro and in cell culture that PKGIa directly phosphorylates the cMyBP-C M-domain on Ser-273, Ser-282, and Ser-302 support an important mechanism through which PKGIα may attenuate pathological remodeling. Accumulating evidence demonstrates that M-domain phosphorylation increases cMyBP-C interaction with the myosin head and improves CM systolic and diastolic function. 15, 23, 24 Furthermore, genetic disruption of cMyBP-C M-domain phosphorylation leads to chronic remodeling, 15, 22, 33, 34 whereas genetic substitution of aspartate at these sites to mimic constitutive phosphorylation limits the chronic cardiac remodeling process in vivo. 15, 22, 26 In human hypertrophied and failing hearts, cMyBP-C phosphorylation is decreased compared with hearts of normal donors. 35 cMyBP-C M-domain phosphorylation increases rapidly after LV pressure overload but is reduced in the remodeled LV. 15 Despite the apparent antiremodeling effect of cMyBP-C M-domain phosphorylation, kinases previously demonstrated to phosphorylate these sites, including protein kinase A, calmodulin kinase II, protein kinase C, and AKT, 22 generally promote rather than inhibit pathological remodeling. Our observations therefore identify PKGIα phosphorylation on cMyBP-C M-domain sites as a novel upstream antiremodeling mechanism of cMyBP-C regulation.
Our finding that sildenafil increases cMyBP-C phosphorylation at Ser-273 in an in vivo model of cardiac remodeling, and HF further supports that PKGIα inhibits cardiac remodeling through regulation of cMyBP-C. Sildenafil inhibits cGMP catalysis by the cGMP-selective phosphodiesterase 5, thus increasing intracellular cGMP and activating PKGI. 2 In the pressure overloaded LV, where phosphodiesterase 5 activity increases significantly, phosphodiesterase 5 inhibition prevents excess cGMP breakdown and promotes PKGI kinase activity, leading to attenuated LV remodeling. 2 Our study demonstrates that, in addition to previously reported antiremodeling effects, sildenafil treatment also increases cMyBP-C phosphorylation in pressure-overloaded hearts. This finding therefore provides evidence that pharmacological PKGI activation increases cMyBP-C phosphorylation on antiremodeling residues. Because cMyBP-C phosphorylation at Ser-273 inhibits cardiac remodeling, 15, 23, 24 we interpret our findings to support that PKGI may normally inhibit pressure overloadinduced remodeling through phosphorylation of cMyBP-C.
Significance of cMyBP-C as a Cardiac Myocyte-Specific Antiremodeling Substrate of PKGIα
Although PKGI inhibits cardiac remodeling in vivo, the downstream myocardial LZ-dependent substrates mediating this effect had not been systematically studied. Our findings that cMyBP-C functions as a CM-specific PKGIα substrate support an antiremodeling function of PKGIα within the CM. These findings also support the broader hypothesis that PKGIα separately regulates vasodilation and myocardial remodeling at least in part through independent sets of substrates. This is of substantial clinical relevance because trials of PKGIα-activating drugs, such as nesiritide, cinaciguat, and sildenafil, have been limited by vasodilating side effects arising from systemic PKGI activation. 1 More recently, the compound LCZ696, which activates PKGI through inhibition of upstream natriuretic peptide degradation, has been shown to improve outcomes in HF, but also to induce excess hypotension. 11 These clinical trial results further highlight the importance of understanding CM-specific PKGIα effectors, such as cMyBP-C, which might serve as therapeutic targets to selectively inhibit remodeling, but avoid excess hypotension arising from systemic PKGI activation.
Limitations
Our study has several limitations. First, although we demonstrate that PKGIα phosphorylates cMyBP-C on 3 critical antiremodeling sites, this study did not explore additional sites on cMyBP-C, which may also be regulated by PKGIα. Second, although we identified PKGI augmentation with sildenafil or cGMP as increasing cMyBP-C phosphorylation in vivo or in the cultured CM, we did not determine the degree to which inhibition of remodeling correlated with phosphorylation on a cell-by-cell or individual mouse level. Therefore, the degree to which the phosphorylation of cMyBP-C correlates with cellular remodeling remains untested. Third, it should be noted that in our initial screen, we determined the molecular species only in bands precipitating with the PKG 1-59 LZ domain, but did not perform mass spectroscopy analysis on the corresponding region of negative control lanes that had no detectable bands. However, we circumvented this limitation by performing Western blot for cMyBP-C on identical pulldown experiments. These findings (Figure 2A ) strongly support that cMyBP-C binds specifically with the WT PKGIα LZ domain and not with the LZ mutant domain. Finally, although cMyBP-C phosphorylation decreases in the human failing heart, 35 our study only examined the PKGIα regulation of cMyBP-C in animal and in vitro experiments. Therefore, although we speculate that PKGI-activating drugs, such as nesiritide, nitrates, sildenafil, and LCZ696, inhibit remodeling by inducing cMyBP-C phosphorylation, this remains untested in humans.
In summary, our study provides the first identification of a myocardial-specific PKGIα antiremodeling substrate. Our findings provide the rationale for broader investigation of PKGIα LZ substrates in the heart as a strategy to identify novel antiremodeling therapies. 
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